Targeted drug plus cholesterol drug for HER2-low breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is testing a combination of a targeted drug (trastuzumab deruxtecan) and a cholesterol-lowering drug (lovastatin) for people with breast cancer that has low or ultra-low HER2 levels. The goal is to see if this combination can shrink tumors or slow cancer growth better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have breast cancer that has spread or can't be removed by surgery, and your tumor has low or ultra-low levels of HER2, a protein found on some cancer cells.
- You can have had no more than one prior chemotherapy treatment, but you can have had many hormone therapies if your cancer is hormone receptor positive.
- Your cancer must be measurable, meaning it can be seen on scans or tests.
- You must be at least 18 years old and able to perform your daily activities with minimal assistance (ECOG performance status of 2 or less).
- Your heart function must be normal (ejection fraction of 50% or higher), and you must not have untreated brain metastases or severe lung disease.
- You must agree to use effective birth control during the study and for 7 months after treatment, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This trial tests a combination of two targeted drugs — anlotinib (which cuts off a tumor's blood supply) and trastuzumab deruxtecan (which attacks HER2-low cancer cells) — for advanced breast cancer that has stopped responding to previous treatments.
This trial tests a combination of two drugs that target HER2-positive breast cancer: trastuzumab deruxtecan (currently the standard) plus a newer drug called pyrotinib. The goal is to see if combining these drugs helps people whose cancer has continued to grow despite taking trastuzumab deruxtecan alone.
This study looks at treatment choices for adults with breast cancer that has spread and cannot be removed by surgery (unresectable metastatic disease). It focuses on people with HER2-low (and some HER2-ultralow) and/or hormone-receptor positive cancer, and compares how well treatments like T-DXd or standard chemotherapy work.
This trial tests two targeted drugs, trastuzumab rezetecan and trastuzumab deruxtecan, to see which works better for HER2-positive breast cancer that has spread or cannot be removed by surgery. These drugs target the HER2 protein on cancer cells to slow or stop their growth.
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.